Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohortResearch in context
Summary: Background: Although terminal complement inhibitors transformed the prognosis of atypical haemolytic uraemic syndrome (aHUS) from dismal to favourable, treatment approaches vary due to the intermittent disease nature and high costs. Occasionally, complement inhibition is applied in infecti...
Saved in:
Similar Items
-
PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1
by: John C. Lieske, et al.
Published: (2025-06-01) -
Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab
by: Franz Schaefer, et al.
Published: (2024-09-01) -
From Multimorbidity to Network Medicine in Patients with Rheumatic Diseases
by: Winston Gilcrease, et al.
Published: (2024-11-01) -
Can Plant-Based Cheese Substitutes Nutritionally and Sensorially Replace Cheese in Our Diet?
by: Andreja Čanžek Majhenič, et al.
Published: (2025-02-01) -
A Caution Against the Use of C5b-9 Endothelial Assay to Support Eculizumab Therapy: A response to Maritati et al.: “Eculizumab first” in the management of posttransplant thrombotic microangiopathy
by: Caroline Duineveld, et al.
Published: (2024-05-01)